

# Daniel P Cahill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8403294/publications.pdf>

Version: 2024-02-01

181  
papers

15,086  
citations

53794

45  
h-index

21540

114  
g-index

185  
all docs

185  
docs citations

185  
times ranked

21131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. <i>Science</i> , 2014, 344, 1396-1401.	12.6	3,648
2	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	28.9	1,408
3	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. <i>Nature</i> , 2016, 539, 309-313.	27.8	875
4	Mesenchymal Differentiation Mediated by NF- $\kappa$ B Promotes Radiation Resistance in Glioblastoma. <i>Cancer Cell</i> , 2013, 24, 331-346.	16.8	856
5	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
6	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. <i>Science</i> , 2017, 355, .	12.6	743
7	A Hypermutation Phenotype and Somatic <i>MSH6</i> Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy. <i>Cancer Research</i> , 2006, 66, 3987-3991.	0.9	383
8	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014, 16, 81-91.	1.2	370
9	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	30.7	359
10	Extreme Vulnerability of IDH1 Mutant Cancers to NAD <sup>+</sup> Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	16.8	327
11	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015, 129, 585-596.	7.7	272
12	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. <i>Cell</i> , 2018, 175, 101-116.e25.	28.9	234
13	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	28.9	210
14	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv310.	6.3	182
15	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	21.4	177
16	Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. <i>Cancer Cell</i> , 2017, 32, 411-426.e11.	16.8	161
17	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909.	7.0	146
18	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	7.0	127

#	ARTICLE	IF	CITATIONS
19	The role of neuropathology in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 531-549.	2.9	120
20	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research, 2016, 22, 4452-4465.	7.0	112
21	Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro-Oncology, 2016, 18, 1656-1663.	1.2	110
22	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nature Communications, 2018, 9, 1474.	12.8	106
23	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research, 2016, 76, 6495-6506.	0.9	105
24	Isocitrate dehydrogenaseâ€ˆmutant glioma: Evolving clinical and therapeutic implications. Cancer, 2017, 123, 4535-4546.	4.1	103
25	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
26	Evidence-based recommendations on categories for extent of resection in diffuse glioma. European Journal of Cancer, 2021, 149, 23-33.	2.8	97
27	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	1.8	89
28	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nature Medicine, 2020, 26, 1280-1284.	30.7	83
29	Updates in prognostic markers for gliomas. Neuro-Oncology, 2018, 20, vii17-vii26.	1.2	78
30	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Advances, 2019, 3, 375-383.	5.2	77
31	â€œReal worldâ€ˆuse of a highly reliable imaging sign: â€œT2-FLAIR mismatchâ€ˆfor identification of IDH mutant astrocytomas. Neuro-Oncology, 2020, 22, 936-943.	1.2	77
32	Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clinical Cancer Research, 2020, 26, 1690-1699.	7.0	76
33	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 378-387.	1.9	75
34	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD+ Depletionâ€ˆMediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.9	74
35	Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. Journal of Neuro-Oncology, 2019, 141, 327-335.	2.9	72
36	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Nonâ€ˆSmall Cell Lung Cancer. Cancer Discovery, 2018, 8, 1598-1613.	9.4	71

#	ARTICLE	IF	CITATIONS
37	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. <i>Neuro-Oncology</i> , 2019, 21, 1401-1411.	1.2	70
38	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	7.1	68
39	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	30.7	67
40	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	7.7	66
41	Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 133-145.	3.8	65
42	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. <i>Cancer</i> , 2019, 125, 2910-2914.	4.1	58
43	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , 2020, 8, 171.	5.2	58
44	The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 565-574.	2.9	57
45	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	7.0	57
46	Glioblastoma care in the elderly. <i>Cancer</i> , 2016, 122, 189-197.	4.1	53
47	Origin of Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 005-010.	1.4	52
48	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 1261-1271.	7.0	50
49	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5.	5.4	49
50	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. <i>CNS Oncology</i> , 2015, 4, 287-294.	3.0	48
51	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
52	The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 591-603.	2.9	38
53	Accelerated progression of IDH mutant glioma after first recurrence. <i>Neuro-Oncology</i> , 2019, 21, 669-677.	1.2	38
54	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	3.7	36

#	ARTICLE	IF	CITATIONS
55	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	12.8	35
56	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. <i>Neurosurgery</i> , 2017, 80, 590-601.	1.1	34
57	Blockade of transforming growth factor $\beta$ signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. <i>International Journal of Cancer</i> , 2017, 141, 2348-2358.	5.1	33
58	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. <i>Acta Neuropathologica</i> , 2020, 140, 89-93.	7.7	32
59	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	12.8	31
60	The role of biopsy in the management of patients with presumed diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 481-501.	2.9	30
61	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. <i>Neuro-Oncology</i> , 2016, 18, now100.	1.2	30
62	Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD <sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. <i>Cancer Discovery</i> , 2020, 10, 1672-1689.	9.4	30
63	Microscale Physiological Events on the Human Cortical Surface. <i>Cerebral Cortex</i> , 2021, 31, 3678-3700.	2.9	29
64	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. <i>Journal of Neuro-Oncology</i> , 2014, 118, 405-412.	2.9	28
65	Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. <i>Neurosurgical Focus</i> , 2016, 41, E2.	2.3	28
66	PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2551-2563.	4.1	28
67	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. <i>PLoS ONE</i> , 2018, 13, e0202860.	2.5	28
68	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , 2019, 85, 204-210.	1.1	28
69	Local Targeting of NAD <sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. <i>Cancer Research</i> , 2020, 80, 5024-5034.	0.9	28
70	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas. <i>Neurosurgery</i> , 2017, 64, 134-138.	1.1	27
71	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , 2021, 4, e2120040.	5.9	27
72	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	7.0	26

#	ARTICLE	IF	CITATIONS
73	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. <i>OncoImmunology</i> , 2020, 9, 1806662.	4.6	26
74	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	13.2	26
75	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. <i>Neuro-Oncology</i> , 2016, 18, 1278-1287.	1.2	25
76	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
77	TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. <i>Neuro-Oncology</i> , 2021, 23, 76-87.	1.2	24
78	Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping. <i>Clinical Neurophysiology</i> , 2019, 130, 1058-1065.	1.5	22
79	MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. <i>Clinical Neurosurgery</i> , 2008, 55, 165-71.	0.2	22
80	Microscale dynamics of electrophysiological markers of epilepsy. <i>Clinical Neurophysiology</i> , 2021, 132, 2916-2931.	1.5	20
81	Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. <i>Journal of Neurosurgery</i> , 2020, , 1-10.	1.6	20
82	ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. <i>Neuro-Oncology</i> , 2022, 24, 888-900.	1.2	20
83	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. <i>Cancer Research</i> , 2020, 80, 5330-5343.	0.9	19
84	Phase II study of pembrolizumab in leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2007-2007.	1.6	19
85	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. <i>Acta Neuropathologica Communications</i> , 2018, 6, 106.	5.2	18
86	Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 562-567.	0.8	18
87	Extent of Resection Versus Molecular Classification. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 95-101.	1.7	18
88	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1α-mutated Human Gliomas. <i>Radiology</i> , 2020, 294, 589-597.	7.3	18
89	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2000-2000.	1.6	18
90	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.4	18

#	ARTICLE	IF	CITATIONS
91	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 75-81.	3.8	17
92	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. Journal of Clinical Oncology, 2020, 38, 2502-2502.	1.6	17
93	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in <i>BRAFV600E</i> -mutant High-grade Glioma. Clinical Cancer Research, 2022, 28, 2425-2439.	7.0	17
94	Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study. Neurosurgery, 2021, 88, 63-73.	1.1	15
95	Sirtuin activation targets IDH-mutant tumors. Neuro-Oncology, 2021, 23, 53-62.	1.2	15
96	A Multi-Institutional Analysis of Factors Influencing Surgical Outcomes for Patients with Newly Diagnosed Grade I Gliomas. World Neurosurgery, 2020, 135, e754-e764.	1.3	14
97	A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood, 2021, 138, 382-386.	1.4	13
98	A Monoclonal Antibody Against $\alpha_5\beta_1$ Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Targeted Oncology, 2019, 14, 479-489.	3.6	12
99	An integrated RF-receive/BO-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7T. Scientific Reports, 2020, 10, 15029.	3.3	12
100	Extent of Resection of Glioblastoma. Neurosurgery Clinics of North America, 2021, 32, 23-29.	1.7	12
101	Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathologica Communications, 2021, 9, 8.	5.2	12
102	Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients. Neurosurgery, 2019, 84, 519-528.	1.1	11
103	Case 10-2010. New England Journal of Medicine, 2010, 362, 1326-1333.	27.0	10
104	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports, 2019, 9, 139.	3.3	9
105	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. Journal of Clinical Neuroscience, 2016, 31, 99-105.	1.5	8
106	TERT Alterations in Progressive Treatment-Resistant Meningiomas. Neurosurgery, 2018, 65, 66-68.	1.1	8
107	Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study. Neurosurgery, 2021, 88, E49-E59.	1.1	8
108	Implementation of <i>TERT</i> promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	8



#	ARTICLE	IF	CITATIONS
109	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2029-2029.	1.6	7
110	Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy. Clinical Neurophysiology, 2021, 132, 1416-1432.	1.5	6
111	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. Neurologia Medico-Chirurgica, 2021, 61, 385-391.	2.2	4
112	IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas.. Journal of Clinical Oncology, 2012, 30, 2019-2019.	1.6	4
113	Case 38-2016. New England Journal of Medicine, 2016, 375, 2381-2389.	27.0	3
114	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. Oncologist, 2019, 24, 402-413.	3.7	3
115	ATPS-852-HYDROXYGLUTARATE DEPLETION IS NOT SUFFICIENT TO INHIBIT GROWTH OF SEVERAL PROGRESSIVE IDH1 MUTANT SOLID CANCER TYPES. Neuro-Oncology, 2015, 17, v37.2-v37.	1.2	2
116	MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. Neuro-Oncology, 2020, 22, 1553-1554.	1.2	2
117	Improving Dâ€²â€²hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€²receive/B<sub>0</sub></sub>â€²shim array coils at 3â€²%T. NMR in Biomedicine, 2022, 35, 2.8 e4621.		2
118	<i>TERT</i> promoter mutations in progressive treatment-resistant meningiomas.. Journal of Clinical Oncology, 2017, 35, 2047-2047.	1.6	2
119	TERT rearrangements to identify a subset of aggressive meningiomas.. Journal of Clinical Oncology, 2018, 36, e14028-e14028.	1.6	2
120	In Vivo Absolute Metabolite Quantification Using a Multiplexed <sc>ERETICâ€²RX</sc> Array Coil for Wholeâ€²Brain <sc>MR</sc> Spectroscopic Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 121-133.	3.4	2
121	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.7	2
122	CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION. Neuro-Oncology, 2018, 20, vi57-vi58.	1.2	1
123	INNV-27. THE IMPACT OF A DEDICATED MULTIDISCIPLINARY TUMOR BOARD ON CARE FOR PATIENTS WITH BRAIN METASTASES. Neuro-Oncology, 2019, 21, vi135-vi136.	1.2	1
124	CBMT-19. THE ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM PROVIDES COLLATERAL SENSITIVITY TO LETHAL TELOMERIC FUSION INDUCED BY TRAPPING PARP INHIBITORS. Neuro-Oncology, 2019, 21, vi37-vi37.	1.2	1
125	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. Neuro-Oncology, 2019, 21, vi111-vi111.	1.2	1
126	Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma. Seminars in Radiation Oncology, 2020, 30, 218-222.	2.2	1



#	ARTICLE	IF	CITATIONS
127	Neurosurgical involvement in clinical trials for CNS tumors. Journal of Neuro-Oncology, 2021, 151, 367-373.	2.9	1
128	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. Neuro-Oncology Advances, 2021, 3, i12-i13.	0.7	1
129	Clinically-actionable Mutations in Posterior Skull Base Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	1
130	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. Journal of Clinical Oncology, 2018, 36, e14041-e14041.	1.6	1
131	The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases.. Journal of Clinical Oncology, 2019, 37, e13585-e13585.	1.6	1
132	IMMU-01. SINGLE CELL SEQUENCING OF MELANOMA BRAIN METASTASES UNVEILS HETEROGENEITY OF THE TUMOR MICROENVIRONMENT IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE. Neuro-Oncology, 2020, 22, ii104-ii104.	1.2	1
133	TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE. Neuro-Oncology, 2020, 22, ii230-ii231.	1.2	1
134	MPH-17CLINICAL AND MOLECULAR CHARACTERIZATION OF LONG-TERM GLIOBLASTOMA SURVIVORS. Neuro-Oncology, 2015, 17, v141.4-v142.	1.2	0
135	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. Neuro-Oncology, 2015, 17, v45.4-v45.	1.2	0
136	Reply to Freyschlag et al. Neuro-Oncology, 2017, 19, 598-599.	1.2	0
137	DRES-16. PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOMA MODELS. Neuro-Oncology, 2017, 19, vi67-vi67.	1.2	0
138	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. Neuro-Oncology, 2017, 19, vi75-vi75.	1.2	0
139	EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING. Neuro-Oncology, 2018, 20, vi82-vi82.	1.2	0
140	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. Neuro-Oncology, 2018, 20, vi106-vi107.	1.2	0
141	MNGI-37. DMD GENOMIC DELETIONS CHARACTERIZE A SUBSET OF PROGRESSIVE/HIGHER-GRADE MENINGIOMAS WITH POOR OUTCOME. Neuro-Oncology, 2018, 20, vi157-vi157.	1.2	0
142	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. Neuro-Oncology, 2018, 20, vi56-vi57.	1.2	0
143	CSIG-34. PI3 KINASE PATHWAY ACTIVATION PROMOTES MALIGNANT PROGRESSION IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology, 2018, 20, vi50-vi50.	1.2	0
144	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. Neuro-Oncology, 2018, 20, vi190-vi190.	1.2	0

#	ARTICLE	IF	CITATIONS
145	CBMT-47. MODULATION OF NAD PATHWAYS AS A THERAPEUTIC STRATEGY FOR TARGETING IDH MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi43-vi43.	1.2	0
146	DRES-05. PREDICTORS OF SENSITIVITY TO COMBINED TEMOZOLOMIDE AND PARP INHIBITOR IN GLIOMA. Neuro-Oncology, 2019, 21, vi72-vi72.	1.2	0
147	RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS. Neuro-Oncology, 2019, 21, vi222-vi222.	1.2	0
148	NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. Neuro-Oncology, 2019, 21, vi163-vi163.	1.2	0
149	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. Neuro-Oncology, 2019, 21, vi58-vi59.	1.2	0
150	Neurologic complications of melanoma. Cancer, 2020, 126, 477-486.	4.1	0
151	BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS. Neuro-Oncology Advances, 2021, 3, i5-i6.	0.7	0
152	DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS. Neuro-Oncology Advances, 2021, 3, i6-i7.	0.7	0
153	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 3059-3059.	1.6	0
154	IMMU-08. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. Neuro-Oncology Advances, 2021, 3, iv6-iv6.	0.7	0
155	Mismatch repair defects underlying temozolomide chemoresistance in recurrent glioblastomas. FASEB Journal, 2008, 22, 172.2.	0.5	0
156	Targetable signaling pathway mutations and progression of IDH<i>-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
157	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
158	Characterizing glioma microenvironment with ultra-high gradient diffusion MRI.. Journal of Clinical Oncology, 2017, 35, 2050-2050.	1.6	0
159	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. Journal of Clinical Oncology, 2020, 38, 2529-2529.	1.6	0
160	Commentary: The Glioma-Network Interface: A Review of the Relationship Between Glioma Molecular Subtype and Intratumoral Function. Neurosurgery, 2021, 88, E273-E274.	1.1	0
161	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. Neuro-Oncology, 2021, 23, vi123-vi123.	1.2	0
162	EXTH-55. TARGETING RECURRENT IDH MUTANT GLIOMA WITH CDK4/6 INHIBITION. Neuro-Oncology, 2021, 23, vi175-vi175.	1.2	0

#	ARTICLE	IF	CITATIONS
163	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. Neuro-Oncology, 2021, 23, vi92-vi92.	1.2	0
164	CBIO-20. HIGH LEVELS OF TERT CONFER SENSITIVITY TO THE DNA HYPOMETHYLATING AGENT DECITABINE (DAC) IN GLIOMAS. Neuro-Oncology, 2021, 23, vi31-vi31.	1.2	0
165	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. Neuro-Oncology, 2021, 23, vi57-vi57.	1.2	0
166	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. Neuro-Oncology, 2021, 23, vi10-vi10.	1.2	0
167	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. Neuro-Oncology, 2021, 23, vi72-vi72.	1.2	0
168	CTIM-01. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. Neuro-Oncology, 2021, 23, vi48-vi49.	1.2	0
169	TAMI-30. LOCAL TARGETING OF NAD+ SALVAGE PATHWAY ALTERS THE IMMUNE TUMOR MICROENVIRONMENT AND ENHANCES CHECKPOINT IMMUNOTHERAPY IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii219-ii219.	1.2	0
170	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. Neuro-Oncology, 2020, 22, ii147-ii147.	1.2	0
171	EXTH-10. COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS. Neuro-Oncology, 2020, 22, ii88-ii89.	1.2	0
172	TMOD-13. RESEARCH RESOURCES FOR OLIGODENDROGLIOMA NOW AVAILABLE TO RESEARCH COMMUNITY. Neuro-Oncology, 2020, 22, ii230-ii230.	1.2	0
173	SURG-12. PREDICTORS OF SURVIVAL AND UTILITY OF INTRAOPERATIVE MRI FOR RESECTION OF GRADE II ASTROCYTOMAS AND OLIGODENDROGLIOMAS: A MULTICENTER ANALYSIS. Neuro-Oncology, 2020, 22, ii205-ii206.	1.2	0
174	CSIG-19. THE DEUBIQUITINASE BRCC3 LINKS ALT TELOMERES TO SUPPRESSION OF INNATE IMMUNITY IN IDH1-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, ii31-ii32.	1.2	0
175	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. Neuro-Oncology, 2020, 22, ii13-ii13.	1.2	0
176	TAMI-36. CONNEXIN 43 BLOCKADE INHIBITS PROLIFERATION IN IDH1-MUTANT GLIOMA CELLS. Neuro-Oncology, 2020, 22, ii220-ii221.	1.2	0
177	TAMI-20. POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITION SEQUESTERS NAD+ TO POTENTIATE THE METABOLIC LETHALITY OF ALKYLATING CHEMOTHERAPY IN IDH MUTANT TUMOR CELLS. Neuro-Oncology, 2020, 22, ii217-ii217.	1.2	0
178	Trabectedin for recurrent WHO grade 2 or 3 meningiomasâ€”paving the road for new opportunities. Neuro-Oncology, 2022, , .	1.2	0
179	Enhancing demethylation-induced differentiation in IDH-mutant glioma. Neuro-Oncology, 2022, , .	1.2	0
180	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-Oncology, 2021, 23, vi49-vi49.	1.2	0

#	ARTICLE	IF	CITATIONS
181	PATH-40. SPORADIC NF2 WILD-TYPE MULTIPLE MENINGIOMAS HARBOR DISTINCT DRIVER MUTATIONS. Neuro-Oncology, 2021, 23, vi124-vi124.	1.2	0